Pfizer: Astra deal would cut R&D spend

Comment on this story
Ian Read1 Reuters. Pfizer chief executive Ian Read.

London - Pfizer chief executive Ian Read said on Tuesday he expected the combined research expenditure of the merged drugmaker would be lower than that of the two separate companies following a takeover of drugmaker AstraZeneca.

Read told a panel of British lawmakers that one of the drivers of his proposed deal was to increase efficiency in order to keep both firms competitive in an increasingly tough marketplace.

The US drugmaker has stirred up a political storm with its $106 billion plan to acquire AstraZeneca, which has been rebuffed by the smaller British company.

The deal would be the largest foreign takeover of a British firm and is opposed by many scientists, trade unions and politicians who fear for British science jobs given Pfizer's track record of cost cutting after past acquisitions. - Reuters

sign up

Comment Guidelines

  1. Please read our comment guidelines.
  2. Login and register, if you haven’ t already.
  3. Write your comment in the block below and click (Post As)
  4. Has a comment offended you? Hover your mouse over the comment and wait until a small triangle appears on the right-hand side. Click triangle () and select "Flag as inappropriate". Our moderators will take action if need be.

  5. Verified email addresses: All users on Independent Media news sites are now required to have a verified email address before being allowed to comment on articles. You are only required to verify your email address once to have full access to commenting on articles. For more information please read our comment guidelines